{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:51:40Z","timestamp":1793199100788,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fujian Cancer Hospital Project","award":["2024YN01"],"award-info":[{"award-number":["2024YN01"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2024J011094, 2024J011083"],"award-info":[{"award-number":["2024J011094, 2024J011083"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Joint Funds for the innovation of science and Technology, Fujian province","award":["2025Y9653"],"award-info":[{"award-number":["2025Y9653"]}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2024QNA055"],"award-info":[{"award-number":["2024QNA055"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04264-z","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T03:37:07Z","timestamp":1771904227000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of neoadjuvant chemotherapy on safety and long-term survival in patients with locally advanced colon cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Jinliang","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhua","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenmeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"3","key":"4264_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4264_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4264_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.6004\/jnccn.2017.0019","volume":"15","author":"CE Klaver","year":"2017","unstructured":"Klaver CE, Gietelink L, Bemelman WA, Wouters MW, Wiggers T, Tollenaar RA, et al. Locally advanced colon cancer: evaluation of current clinical practice and treatment outcomes at the population level. J Natl Compr Canc Netw. 2017;15(2):181\u201390. https:\/\/doi.org\/10.6004\/jnccn.2017.0019.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"4264_CR4","doi-asserted-by":"publisher","first-page":"598","DOI":"10.21147\/j.issn.1000-9604.2016.06.06","volume":"28","author":"H Zhou","year":"2016","unstructured":"Zhou H, Song Y, Jiang J, Niu H, Zhao H, Liang J, et al. A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer. Chin J Cancer Res. 2016;28(6):598\u2013605. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2016.06.06.","journal-title":"Chin J Cancer Res"},{"issue":"10","key":"4264_CR5","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10151-020-02289-4","volume":"24","author":"J Arredondo","year":"2020","unstructured":"Arredondo J, Pastor E, Sim\u00f3 V, Beltr\u00e1n M, Casta\u00f1\u00f3n C, Magdaleno MC, et al. Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review. Tech Coloproctol. 2020;24(10):1001\u201315. https:\/\/doi.org\/10.1007\/s10151-020-02289-4.","journal-title":"Tech Coloproctol"},{"issue":"5","key":"4264_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00384-022-04159-x","volume":"37","author":"T Tominaga","year":"2022","unstructured":"Tominaga T, Nonaka T, Oyama S, Shiraishi T, Takeshita H, Hisanaga M, et al. Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and\/or N2 disease: a multicenter, propensity score-matched analysis. Int J Colorectal Dis. 2022;37(5):1181\u20138. https:\/\/doi.org\/10.1007\/s00384-022-04159-x.","journal-title":"Int J Colorectal Dis"},{"issue":"19","key":"4264_CR7","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andr\u00e9","year":"2009","unstructured":"Andr\u00e9 T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109\u201316. https:\/\/doi.org\/10.1200\/JCO.2008.20.6771.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4264_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1001\/jamasurg.2021.1939","volume":"156","author":"DB Stewart","year":"2021","unstructured":"Stewart DB. Updated USPSTF guidelines for colorectal cancer screening: the earlier the better. JAMA Surg. 2021;156(8):708\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2021.1939.","journal-title":"JAMA Surg"},{"issue":"10","key":"4264_CR9","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00384-021-03945-3","volume":"36","author":"R Gosavi","year":"2021","unstructured":"Gosavi R, Chia C, Michael M, Heriot AG, Warrier SK, Kong JC. Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2021;36(10):2063\u201370. https:\/\/doi.org\/10.1007\/s00384-021-03945-3.","journal-title":"Int J Colorectal Dis"},{"key":"4264_CR10","doi-asserted-by":"publisher","first-page":"102676","DOI":"10.1016\/j.ctrv.2023.102676","volume":"123","author":"A Audisio","year":"2024","unstructured":"Audisio A, Fazio R, Dapr\u00e0 V, Assaf I, Hendlisz A, Sclafani F. Neoadjuvant chemotherapy for early-stage colon cancer. Cancer Treat Rev. 2024;123:102676. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102676.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"4264_CR11","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/JCO.22.00046","volume":"41","author":"D Morton","year":"2023","unstructured":"Morton D, Seymour M, Magill L, Handley K, Glasbey J, Glimelius B, et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. 2023;41(8):1541\u201352. https:\/\/doi.org\/10.1200\/JCO.22.00046.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4264_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jtcvs.2023.12.030","volume":"168","author":"YK Yu","year":"2024","unstructured":"Yu YK, Meng FY, Wei XF, Chen XK, Li HM, Liu Q, et al. Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2024;168(2):417-28.e3. https:\/\/doi.org\/10.1016\/j.jtcvs.2023.12.030.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"25","key":"4264_CR13","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.23.02167","volume":"42","author":"YK Kang","year":"2024","unstructured":"Kang YK, Kim HD, Yook JH, Park YK, Lee JS, Kim YW, et al. Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: updated overall survival outcomes from phase III PRODIGY. J Clin Oncol. 2024;42(25):2961\u20135. https:\/\/doi.org\/10.1200\/JCO.23.02167.","journal-title":"J Clin Oncol"},{"key":"4264_CR14","doi-asserted-by":"publisher","first-page":"103739","DOI":"10.1016\/j.breast.2024.103739","volume":"76","author":"NP Quirke","year":"2024","unstructured":"Quirke NP, Cullinane C, Turk MA, Shafique N, Evoy D, Geraghty J, et al. Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period. Breast. 2024;76:103739. https:\/\/doi.org\/10.1016\/j.breast.2024.103739.","journal-title":"Breast"},{"issue":"1","key":"4264_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1186\/s12885-024-12634-7","volume":"24","author":"M Biniaz","year":"2024","unstructured":"Biniaz M, Moradi A, Basit MG, Pashaki AS, Dehghan A, Mohammadian K. Combination of neoadjuvant and adjuvant chemotherapy with FOLFOX compared with adjuvant chemotherapy in management of locally advanced rectal cancers: a randomized trial of a promising therapeutic approach. BMC Cancer. 2024;24(1):863. https:\/\/doi.org\/10.1186\/s12885-024-12634-7.","journal-title":"BMC Cancer"},{"key":"4264_CR16","doi-asserted-by":"publisher","first-page":"e240029","DOI":"10.6004\/jnccn.2024.0029","volume":"22","author":"AB Benson","year":"2024","unstructured":"Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, et al. Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22:e240029. https:\/\/doi.org\/10.6004\/jnccn.2024.0029.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"4264_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/DCR.0000000000002323","volume":"65","author":"JD Vogel","year":"2022","unstructured":"Vogel JD, Felder SI, Bhama AR, Hawkins AT, Langenfeld SJ, Shaffer VO, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer. Dis Colon Rectum. 2022;65(2):148\u201377. https:\/\/doi.org\/10.1097\/DCR.0000000000002323.","journal-title":"Dis Colon Rectum"},{"issue":"12","key":"4264_CR18","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.annonc.2021.08.1752","volume":"32","author":"T Yoshino","year":"2021","unstructured":"Yoshino T, Argil\u00e9s G, Oki E, Martinelli E, Taniguchi H, Arnold D, et al. Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Ann Oncol. 2021;32(12):1496\u2013510. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1752.","journal-title":"Ann Oncol"},{"issue":"6","key":"4264_CR19","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/DCR.0000000000003263","volume":"67","author":"A Loria","year":"2024","unstructured":"Loria A, Ammann AM, Olowokure OO, Paquette IM, Justiniano CF. Systematic review of neoadjuvant immunotherapy for mismatch repair deficient locally advanced colon cancer: an emerging strategy. Dis Colon Rectum. 2024;67(6):762\u201371. https:\/\/doi.org\/10.1097\/DCR.0000000000003263.","journal-title":"Dis Colon Rectum"},{"issue":"6","key":"4264_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40264-023-01305-4","volume":"46","author":"MA Serageldin","year":"2023","unstructured":"Serageldin MA, Kassem AB, El-Kerm Y, Helmy MW, El-Mas MM, El-Bassiouny NA. The effect of Metformin on chemotherapy-induced toxicities in non-diabetic breast cancer patients: a randomised controlled study. Drug Saf. 2023;46(6):587\u201399. https:\/\/doi.org\/10.1007\/s40264-023-01305-4.","journal-title":"Drug Saf"},{"issue":"1","key":"4264_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/DCR.0000000000000266","volume":"58","author":"AG Mace","year":"2015","unstructured":"Mace AG, Pai RK, Stocchi L, Kalady MF. American Joint Committee on Cancer and College of American Pathologists regression grade: a new prognostic factor in rectal cancer. Dis Colon Rectum. 2015;58(1):32\u201344. https:\/\/doi.org\/10.1097\/DCR.0000000000000266.","journal-title":"Dis Colon Rectum"},{"issue":"8","key":"4264_CR22","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/DCR.0000000000000806","volume":"60","author":"T J\u00e4ger","year":"2017","unstructured":"J\u00e4ger T, Neureiter D, Urbas R, Klieser E, Hitzl W, Emmanuel K, et al. Applicability of American Joint Committee on Cancer and College of American Pathologists regression grading system in rectal cancer. Dis Colon Rectum. 2017;60(8):815\u201326. https:\/\/doi.org\/10.1097\/DCR.0000000000000806.","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"4264_CR23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1186\/s12885-022-10125-1","volume":"22","author":"MY Lai","year":"2022","unstructured":"Lai MY, Kang SY, Sun YT, Quan TT, Lu SX, He CY, et al. Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer. BMC Cancer. 2022;22(1):1031. https:\/\/doi.org\/10.1186\/s12885-022-10125-1.","journal-title":"BMC Cancer"},{"issue":"6","key":"4264_CR24","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.3892\/ol.2015.3101","volume":"9","author":"J Xiao","year":"2015","unstructured":"Xiao J, Tan Y, Li W, Gong J, Zhou Z, Huang Y, et al. Tumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: results from a prospective study. Oncol Lett. 2015;9(6):2680\u20136. https:\/\/doi.org\/10.3892\/ol.2015.3101.","journal-title":"Oncol Lett"},{"issue":"1","key":"4264_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12893-018-0419-y","volume":"18","author":"M Osseis","year":"2018","unstructured":"Osseis M, Esposito F, Lim C, Doussot A, Lahat E, Fuentes L, et al. Impact of postoperative complications on long-term survival following surgery for T4 colorectal cancer. BMC Surg. 2018;18(1):87. https:\/\/doi.org\/10.1186\/s12893-018-0419-y.","journal-title":"BMC Surg"},{"issue":"3","key":"4264_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/his.15193","volume":"85","author":"NM Badr","year":"2024","unstructured":"Badr NM, Zaakouk M, Zhang Q, Kearns D, Kong A, Shaaban AM. Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist. Histopathology. 2024;85(3):437\u201350. https:\/\/doi.org\/10.1111\/his.15193.","journal-title":"Histopathology"},{"issue":"5","key":"4264_CR27","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.21037\/qims-23-1621","volume":"14","author":"X Meng","year":"2024","unstructured":"Meng X, Liu M, Yang D, Jin H, Liu Y, Xu H, et al. Multiparametric magnetic resonance imaging-based assessment of the effect of adenomyosis on determining the depth of myometrial invasion in endometrial cancer. Quant Imaging Med Surg. 2024;14(5):3717\u201330. https:\/\/doi.org\/10.21037\/qims-23-1621.","journal-title":"Quant Imaging Med Surg"},{"issue":"1","key":"4264_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003.","journal-title":"Ann Oncol"},{"issue":"1","key":"4264_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/oncolo\/oyac209","volume":"28","author":"Z Hao","year":"2023","unstructured":"Hao Z, Parasramka S, Chen Q, Jacob A, Huang B, Mullett T, et al. Neoadjuvant versus adjuvant chemotherapy for resectable metastatic colon cancer in non-academic and academic programs. Oncologist. 2023;28(1):48\u201358. https:\/\/doi.org\/10.1093\/oncolo\/oyac209.","journal-title":"Oncologist"},{"issue":"12","key":"4264_CR30","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.hpb.2021.04.026","volume":"23","author":"M Di Martino","year":"2021","unstructured":"Di Martino M, Primavesi F, Syn N, Dorcaratto D, de la Hoz Rodr\u00edguez \u00c1, Dupr\u00e9 A, et al. Perioperative chemotherapy versus surgery alone for resectable colorectal liver metastases: an international multicentre propensity score matched analysis on long-term outcomes according to established prognostic risk scores. HPB (Oxford). 2021;23(12):1873\u201385. https:\/\/doi.org\/10.1016\/j.hpb.2021.04.026.","journal-title":"HPB (Oxford)"},{"issue":"11","key":"4264_CR31","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.1245\/s10434-022-12027-9","volume":"29","author":"M Di Martino","year":"2022","unstructured":"Di Martino M, Primavesi F, Syn N, Dorcaratto D, de la Hoz Rodr\u00edguez \u00c1, Dupr\u00e9 A, et al. Long-term outcomes of perioperative versus neoadjuvant chemotherapy for resectable colorectal liver metastases: an international multicentre propensity-score matched analysis with stratification by contemporary risk-scoring. Ann Surg Oncol. 2022;29(11):6829\u201342. https:\/\/doi.org\/10.1245\/s10434-022-12027-9.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"4264_CR32","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/SLA.0000000000003454","volume":"271","author":"M Karoui","year":"2020","unstructured":"Karoui M, Rullier A, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, et al. Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22). Ann Surg. 2020;271(4):637\u201345. https:\/\/doi.org\/10.1097\/SLA.0000000000003454.","journal-title":"Ann Surg"},{"issue":"1","key":"4264_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00384-023-04482-x","volume":"38","author":"MG Davey","year":"2023","unstructured":"Davey MG, Amir AH, Ryan OK, Donnelly M, Donlon NE, Regan M, et al. Evaluating the oncological safety of neoadjuvant chemotherapy in locally advanced colon carcinoma: a systematic review and meta-analysis of randomised clinical trials and propensity-matched studies. Int J Colorectal Dis. 2023;38(1):193. https:\/\/doi.org\/10.1007\/s00384-023-04482-x.","journal-title":"Int J Colorectal Dis"},{"issue":"25","key":"4264_CR34","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1200\/JCO.23.01889","volume":"42","author":"H Hu","year":"2024","unstructured":"Hu H, Zhang J, Li Y, Wang X, Wang Z, Wang H, et al. Neoadjuvant chemotherapy with oxaliplatin and fluoropyrimidine versus upfront surgery for locally advanced colon cancer: the randomized, phase III OPTICAL trial. J Clin Oncol. 2024;42(25):2978\u201388. https:\/\/doi.org\/10.1200\/JCO.23.01889.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4264_CR35","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","volume":"14","author":"B Nordlinger","year":"2013","unstructured":"Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(13)70447-9.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4264_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/SLA.0000000000006145","volume":"280","author":"FOxTROT Collaborating Group","year":"2024","unstructured":"FOxTROT Collaborating Group. Risk of bowel obstruction in patients undergoing neoadjuvant chemotherapy for high-risk colon cancer: a nested case-control-matched analysis of an international, multicenter, randomized controlled trial (FOxTROT). Ann Surg. 2024;280(2):283\u201393. https:\/\/doi.org\/10.1097\/SLA.0000000000006145.","journal-title":"Ann Surg"},{"issue":"5","key":"4264_CR37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/SLA.0000000000006472","volume":"280","author":"N Pecorelli","year":"2024","unstructured":"Pecorelli N, Guarneri G, Di Salvo F, Vallorani A, Limongi C, Corsi G, et al. The impact of postoperative complications on recovery of health-related quality of life and functional capacity after pancreatectomy: findings from a prospective observational study. Ann Surg. 2024;280(5):719\u201327. https:\/\/doi.org\/10.1097\/SLA.0000000000006472.","journal-title":"Ann Surg"},{"issue":"1","key":"4264_CR38","doi-asserted-by":"publisher","first-page":"19132","DOI":"10.1038\/s41598-024-67813-0","volume":"14","author":"M Sier","year":"2024","unstructured":"Sier M, Dekkers SL, Tweed T, Bakens M, Nel J, van Bastelaar J, et al. Morbidity after accelerated enhanced recovery protocol for colon cancer surgery. Sci Rep. 2024;14(1):19132. https:\/\/doi.org\/10.1038\/s41598-024-67813-0.","journal-title":"Sci Rep"},{"issue":"2","key":"4264_CR39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00595-024-02906-x","volume":"55","author":"M Zenitani","year":"2024","unstructured":"Zenitani M, Nishikawa M, Takemura R, Sakai D, Yoshida M, Noguchi Y, et al. Effect of surgical complications on outcomes of children with hepatoblastoma: a retrospective cohort study. Surg Today. 2024;55(2):197\u2013204. https:\/\/doi.org\/10.1007\/s00595-024-02906-x.","journal-title":"Surg Today"},{"issue":"1","key":"4264_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00423-023-03094-x","volume":"408","author":"A Lynch","year":"2023","unstructured":"Lynch A, Arean-Sanz R, Ore AS, Cataldo G, Crowell K, Fabrizio A, et al. Impact of neoadjuvant chemotherapy for locally advanced colon cancer on postoperative complications. Langenbecks Arch Surg. 2023;408(1):365. https:\/\/doi.org\/10.1007\/s00423-023-03094-x.","journal-title":"Langenbecks Arch Surg"},{"issue":"11","key":"4264_CR41","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3390\/medicina58111505","volume":"58","author":"W Zeng","year":"2022","unstructured":"Zeng W, Liu Y, Wang C, Yang C, Lin S, Li W. Efficacy and safety of neoadjuvant chemotherapy combined with adjuvant chemotherapy for locally advanced colon cancer: a propensity score-matching analysis. Medicina (Kaunas). 2022;58(11):1505. https:\/\/doi.org\/10.3390\/medicina58111505.","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"4264_CR42","doi-asserted-by":"publisher","first-page":"e780","DOI":"10.1002\/onco.13707","volume":"26","author":"HY Chen","year":"2021","unstructured":"Chen HY, Feng LL, Li M, Ju HQ, Ding Y, Lan M, et al. College of American pathologists tumor regression grading system for long-term outcome in patients with locally advanced rectal cancer. Oncologist. 2021;26(5):e780\u201393. https:\/\/doi.org\/10.1002\/onco.13707.","journal-title":"Oncologist"},{"issue":"1","key":"4264_CR43","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1186\/s12885-023-11508-8","volume":"23","author":"C Sun","year":"2023","unstructured":"Sun C, Niu P, Zhang X, Zhao L, Wang W, Luan X, et al. Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: a real-world study. BMC Cancer. 2023;23(1):996. https:\/\/doi.org\/10.1186\/s12885-023-11508-8.","journal-title":"BMC Cancer"},{"issue":"3","key":"4264_CR44","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00280-019-03893-4","volume":"84","author":"X Xu","year":"2019","unstructured":"Xu X, Zheng G, Zhang T, Zhao Y, Zheng Z. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response. Cancer Chemother Pharmacol. 2019;84(3):635\u201346. https:\/\/doi.org\/10.1007\/s00280-019-03893-4.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4264_CR45","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.ijrobp.2009.03.066","volume":"76","author":"JH Kang","year":"2010","unstructured":"Kang JH, Kim YC, Kim H, Kim YW, Hur H, Kim JS, et al. Tumor volume changes assessed by three-dimensional magnetic resonance volumetry in rectal cancer patients after preoperative chemoradiation: the impact of the volume reduction ratio on the prediction of pathologic complete response. Int J Radiat Oncol Biol Phys. 2010;76(4):1018\u201325. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.03.066.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"4264_CR46","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1002\/cam4.3044","volume":"9","author":"T Yokose","year":"2020","unstructured":"Yokose T, Kitago M, Matsusaka Y, Masugi Y, Shinoda M, Yagi H, et al. Usefulness of (18) F-fluorodeoxyglucose positron emission tomography\/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Cancer Med. 2020;9(12):4059\u201368. https:\/\/doi.org\/10.1002\/cam4.3044.","journal-title":"Cancer Med"},{"issue":"2","key":"4264_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41416-022-01801-x","volume":"127","author":"X Pang","year":"2022","unstructured":"Pang X, Xie P, Yu L, Chen H, Zheng J, Meng X, et al. A new magnetic resonance imaging tumour response grading scheme for locally advanced rectal cancer. Br J Cancer. 2022;127(2):268\u201377. https:\/\/doi.org\/10.1038\/s41416-022-01801-x.","journal-title":"Br J Cancer"},{"issue":"9","key":"4264_CR48","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017;3(9):1197\u2013203. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6762.","journal-title":"JAMA Oncol"},{"issue":"13","key":"4264_CR49","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1158\/1078-0432.CCR-19-3728","volume":"26","author":"A Cercek","year":"2020","unstructured":"Cercek A, Dos Santos Fernandes G, Roxburgh CS, Ganesh K, Ng S, Sanchez-Vega F, et al. Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin Cancer Res. 2020;26(13):3271\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3728.","journal-title":"Clin Cancer Res"},{"issue":"35","key":"4264_CR50","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","volume":"37","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37(35):3392\u2013400. https:\/\/doi.org\/10.1200\/JCO.19.01124.","journal-title":"J Clin Oncol"},{"key":"4264_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv438","author":"D Tougeron","year":"2016","unstructured":"Tougeron D, Mouillet G, Trouilloud I, Lecomte T, Coriat R, Aparicio T, et al. Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study. J Natl Cancer Inst. 2016. https:\/\/doi.org\/10.1093\/jnci\/djv438.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"4264_CR52","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, den Van Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566\u201376. https:\/\/doi.org\/10.1038\/s41591-020-0805-8.","journal-title":"Nat Med"},{"issue":"1","key":"4264_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","volume":"7","author":"H Hu","year":"2022","unstructured":"Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(1):38\u201348. https:\/\/doi.org\/10.1016\/S2468-1253(21)00348-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4264_CR54","doi-asserted-by":"publisher","first-page":"1352660","DOI":"10.3389\/fonc.2024.1352660","volume":"14","author":"Y Liang","year":"2024","unstructured":"Liang Y, Liao H, Shi H, Li T, Liu Y, Yuan Y, et al. Risk stratification of stage II rectal mucinous adenocarcinoma to predict the benefit of adjuvant chemotherapy following neoadjuvant chemoradiation and surgery. Front Oncol. 2024;14:1352660. https:\/\/doi.org\/10.3389\/fonc.2024.1352660.","journal-title":"Front Oncol"},{"issue":"4","key":"4264_CR55","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10151-013-1099-3","volume":"18","author":"M Chand","year":"2014","unstructured":"Chand M, Yu S, Swift RI, Brown G. Mucinous carcinoma of the rectum: a distinct clinicopathological entity. Tech Coloproctol. 2014;18(4):335\u201344. https:\/\/doi.org\/10.1007\/s10151-013-1099-3.","journal-title":"Tech Coloproctol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04264-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04264-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04264-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:29:14Z","timestamp":1774884554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04264-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4264"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04264-z","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles outlined in the Declaration of Helsinki and received approval from the Ethics Committee of Fujian Cancer Hospital (Approval No. K2024-180-01). Given the retrospective nature of the study, the requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}